| HOME >> MEDICINE >> TECHNOLOGY |
MEMPHIS, Tenn., May 01, 2007 /PRNewswire-USNewswire/ -- The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.
Peramivir, an antiviral drug, blocks the ability of influenza viruses to use an enzyme called neuraminidase, thus preventing the release of new virus particles and their spread from one infected cell to another.
The researchers reported 100 percent survival among 10 infected mice given intramuscular injections of peramivir daily for eight days. The drug also inhibited the replication of the deadly strain of H5N1 virus in the lung, brain and spleen. The key to the high survival rate was treating the infected mice within 24 hours after infection with H5N1 and continuing the treatment for eight days.
"Peramivir should be given as soon as H5N1 infection is suspected, since onset of symptoms in infected humans can be delayed," said David A. Boltz, Ph.D., a postdoctoral fellow in the laboratory of Robert G. Webster in the Infectious Diseases department at St. Jude. "The drug could also be given as a preventive measure during an outbreak to decrease the risk of infection." Boltz is first author of a paper that was presented Mon., April 30 at the 20th International Conference on Antiviral Research in Palm Springs, Calif.
"We were surprised that we could also see a 40 percent survival
rate among mice after just a single dose of peramivir," said Elena
A. Govorkova, Ph.D., a scientific manager in the Infectious
Diseases department at St. Jude. Govorkova is the paper's senior
author.
'"/>